IDEAYA Biosciences Statistics
Share Statistics
IDEAYA Biosciences has 86.43M shares outstanding. The number of shares has increased by 15.92% in one year.
| Shares Outstanding | 86.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.31% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 77.42M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 9.08M, so 10.5% of the outstanding shares have been sold short.
| Short Interest | 9.08M |
| Short % of Shares Out | 10.5% |
| Short % of Float | 11.72% |
| Short Ratio (days to cover) | 8.8 |
Valuation Ratios
The PE ratio is -18.12 and the forward PE ratio is -11.39.
| PE Ratio | -18.12 |
| Forward PE | -11.39 |
| PS Ratio | 87.52 |
| Forward PS | 32.3 |
| PB Ratio | 3.3 |
| P/FCF Ratio | -17.4 |
| PEG Ratio | n/a |
Enterprise Valuation
IDEAYA Biosciences Inc. has an Enterprise Value (EV) of 1.89B.
| EV / Earnings | -16.75 |
| EV / Sales | 80.92 |
| EV / EBITDA | -14.51 |
| EV / EBIT | -14.08 |
| EV / FCF | -16.09 |
Financial Position
The company has a current ratio of 19.65, with a Debt / Equity ratio of 0.
| Current Ratio | 19.65 |
| Quick Ratio | 19.65 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.18% and return on capital (ROIC) is -21.54%.
| Return on Equity (ROE) | -0.18% |
| Return on Assets (ROA) | -0.17% |
| Return on Capital (ROIC) | -21.54% |
| Revenue Per Employee | 188.59K |
| Profits Per Employee | -910.98K |
| Employee Count | 124 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -43.9% in the last 52 weeks. The beta is 0.86, so IDEAYA Biosciences 's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -43.9% |
| 50-Day Moving Average | 26.88 |
| 200-Day Moving Average | 34.87 |
| Relative Strength Index (RSI) | 32.3 |
| Average Volume (20 Days) | 894.88K |
Income Statement
In the last 12 months, IDEAYA Biosciences had revenue of 23.39M and earned -112.96M in profits. Earnings per share was -1.96.
| Revenue | 23.39M |
| Gross Profit | 19.38M |
| Operating Income | -134.43M |
| Net Income | -112.96M |
| EBITDA | -130.42M |
| EBIT | -134.43M |
| Earnings Per Share (EPS) | -1.96 |
Balance Sheet
The company has 157.02M in cash and 2.87M in debt, giving a net cash position of 154.15M.
| Cash & Cash Equivalents | 157.02M |
| Total Debt | 2.87M |
| Net Cash | 154.15M |
| Retained Earnings | -348.36M |
| Total Assets | 1.24B |
| Working Capital | 891.55M |
Cash Flow
In the last 12 months, operating cash flow was -115.22M and capital expenditures -2.37M, giving a free cash flow of -117.59M.
| Operating Cash Flow | -115.22M |
| Capital Expenditures | -2.37M |
| Free Cash Flow | -117.59M |
| FCF Per Share | -2.04 |
Margins
Gross margin is 82.86%, with operating and profit margins of -574.85% and -483.05%.
| Gross Margin | 82.86% |
| Operating Margin | -574.85% |
| Pretax Margin | -483.05% |
| Profit Margin | -483.05% |
| EBITDA Margin | -557.71% |
| EBIT Margin | -574.85% |
| FCF Margin | -502.85% |
Dividends & Yields
IDYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.62% |
| FCF Yield | -5.99% |
Analyst Forecast
The average price target for IDYA is $53, which is 133.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $53 |
| Price Target Difference | 133.2% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 22.11 |
| Piotroski F-Score | 2 |